PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042554
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042554
Needle-Free Injection System Market size was valued at US$ 241.82 Million in 2025, expanding at a CAGR of 17.98% from 2026 to 2033.
A Needle-Free Injection System (NFIS) is an advanced drug delivery method meant to manage medicines or vaccines without using a traditional needle. Instead of piercing the skin with a sharp item, it uses measured energy like high pressure, gas, or electrical energy to generate a fine liquid or powder jet that passes through the skin. This allows the medicine to spread through different layers of tissue, depending on medical requirements. The system is mainly developed to improve patient comfort, reduce pain, and lower the risk of needle-related injuries and cross-contamination, making it a safer alternative in many clinical situations. International health authorities such as the World Health Organization have consistently promoted safer injection practices to reduce infection risks and accidental needle injuries, encouraging wider interest in alternative drug delivery methods. Similarly, guidance from the Centers for Disease Control and Prevention supports improved injection safety and medical waste reduction, which aligns with the use of needle-free technologies in clinical settings. The UNICEF also supports large-scale vaccine delivery across many countries, emphasizing safe injection equipment in immunization supply systems.
Needle-Free Injection System Market- Market Dynamics
Growing emphasis on healthcare efficiency and medical waste reduction
Growing emphasis on healthcare efficiency and medical waste reduction is becoming an important factor for the sector as healthcare systems are under continuous pressure to deliver safer care while managing resources more effectively. Traditional needle-based injections generate large volumes of hazardous waste, including used syringes and sharp disposal materials, which require strict handling, storage, and disposal processes. This adds operational burden for hospitals and increases the need for safer and more streamlined choices. The Health Canada encourages safe medical waste handling and reduced dependence on disposable sharps in healthcare facilities. The German Federal Ministry of Health supports sustainable healthcare practices and improved hospital waste management systems.
Furthermore, the Australian Department of Health and Aged Care encourages infection control and environmentally safer clinical measures. On the other side, Portal Instruments is developing precision needle-free systems aimed at simplifying drug administration while reducing disposal requirements. Similarly, Antares Pharma has worked on advanced injector technologies designed to improve patient convenience and reduce reliance on traditional needles.
The Global Needle-Free Injection System Market is segmented on the basis of Product, Application, Type, Technology, End User, and Region.
As per product classification, the market is divided into two types: fillable needle-free injectors and prefilled needle-free injectors. The prefilled needle-free injectors tend to play a more important role, as they offer ready-to-use administration, reducing preparation steps and improving consistency in drug delivery. This format is particularly suitable for vaccination programs and emergency care where speed and accuracy are required, while also limiting handling errors associated with manual filling. For example, PharmaJet has supported needle-free vaccination delivery through collaborations with public health immunization initiatives, enabling broader use of its prefilled jet injector systems. Similarly, Crossject has developed its ZENEO platform as a prefilled, needle-free emergency injector designed for rapid drug administration in critical situations.
According to end-user categories, the market varies into four types. Among those, hospitals maintain its presence in the acceptance of needle-free injection systems, as they manage a varied range of treatments that need accurate, safe, and precise drug management. These settings also manage higher patient flow and complex procedures, making safety and efficiency important considerations. Needle-free systems support infection control protocols and reduce handling risks, which aligns with hospital operational needs and clinical standards. For example, Medical International Technology has developed needle-free injection devices that are used in clinical and hospital environments for vaccination and routine drug delivery. Correspondingly, Injex Pharma GmbH has introduced needle-free injection systems designed for medical professionals to improve patient comfort and reduce needle-related risks in treatment settings.
Needle-Free Injection System Market- Geographical Insights
The regional viewpoint for needle-free injection systems highlights how public health frameworks and innovation trends vary across healthcare systems. In North America, the space is formed by a healthcare atmosphere that emphasizes safety, efficiency, and innovation in routine medical practices. Government-linked evidence from Centers for Disease Control and Prevention indicates that nearly 600,000 needlestick injuries occur annually in the United States, reflecting continued occupational exposure risks in clinical settings. While the same agency features that unsafe injection practices can transmit infections such as hepatitis and HIV, reinforcing the need for safer alternatives. Simultaneously, direction from World Health Organization supports the adoption of safer injection technologies to limit disease spread and improve patient protection. On the other side, PharmaJet has reported use of its needle-free systems in immunization programs supporting vaccine delivery without sharps. Similarly, Portal Instruments is advancing digitally controlled, high-pressure injection platforms designed for biologic therapies.
China Needle-Free Injection System Market- Country Insights
In this view, China approach imitates a measured move to safer and more effective healthcare delivery. Healthcare authorities are engaging increasing attention on safer treatment procedures, mainly those that can decrease discomfort and minimize risks related with conventional needles. For example, the National Health Commission of the People's Republic of China has emphasized safe injection practices within its immunization guidelines, noting that reducing needle-related injuries remains an important public health focus. In addition, data from the China Center for Disease Control and Prevention indicate that the country administers billions of vaccine doses annually under its national immunization program, creating interest in alternative delivery methods that may improve convenience and compliance. Among industry applicants, Shanghai Kindly Medical Instruments has reported expanding its portfolio of minimally invasive and drug-delivery devices, including needle-free technologies, reflecting domestic capability building.
Through the development in drug-delivery technologies and rising preference for safer administration methods, the Needle-Free Injection System market is formed by the presence of both innovators and manufacturers. Companies such as Crossject, Portal Instruments, Medical International Technology (MIT Canada), Valeritas, and Endo International are actively working to reinforce their position via product refinement and strategic collaborations. Their contributions reach users thru hospitals, public health programs, distributors, and digital platforms, ensuring broader accessibility. They focus on aspects such as ease of use, device precision, cost balance, and technological consistency to preserve importance. For instance, Portal Instruments partnered with Takeda Pharmaceutical Company to advance needle-free delivery solutions for biologics. Similarly, Crossject progressed its emergency drug delivery platform in coordination with public health authorities. The investment in research, partnerships, and supply development is determining the steady evolution in a practical and measured way.
In March 2025, PharmaJet partnered with World Health Organization to expand the use of needle-free delivery for polio and measles vaccination programs in low-resource settings. The collaboration is intended to support safer immunization practices and reduce needle-associated risks.
In January 2025, Inovio Pharmaceuticals advanced its intradermal DNA vaccine delivery platform using needle-free electroporation devices, strengthening its pipeline for infectious disease immunization. The advancement enhances DNA vaccine delivery efficiency, supporting improved immune response, broader immunization potential, and continued progress in needle-free technologies.